BRIEF-JPMorgan& Co's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 8.29%, HKEX Says

JPMorgan Increases Stake in Hengrui Pharma (01276) by 3.88 Million Shares at HK$72.60 per Share

JPMorgan Chase & Co's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 8.29% on Dec 9 From 6.79% - HKEX

HENGRUI PHARMA's Ovarian Cancer Drug Fuzuloparib (FZOCUS-1 Study) Published in Top Oncology Journal "CA"

Hengrui Medicine's Unit Gets Nod to Trial Heart Failure Drug

Guosen Securities: FXI Inhibitors Poised as Next-Gen Anticoagulants, Recommends Focus on Hengrui Pharma (600276.SH)

BRIEF-Morgan Stanley's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Decreases To 2.76% On Dec 8 - HKEX

Jiangsu Hengrui Medicine Co. Ltd. Announces Date for 2025 Second Extraordinary Shareholders' Meeting

Hengrui Pharma Facilitates Chinese Medical Excellence at Italian Digestive Surgery Conference for Second Consecutive Year

HENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List

Jiangsu Hengrui Medicine Drugs Added to China’s National Reimbursement Drug List

Jiangsu Hengrui Medicine Appoints Zhu Guoxin as Senior Vice President at Board Meeting

FTSE China 50 Index Rebalance: Adds CHINAHONGQIAO (01378), CATL (03750), HENGRUI PHARMA (01276), Removes CSC (06066) and Others

GIC Private Limited Increases Stake in Hengrui Pharma (01276) by 422,400 Shares at HK$74.96 per Share

Morgan Stanley Increases Stake in Hengrui Pharma by 1.77 Million Shares at Average Price of HK$69.65

Wellington Management Group LLP Increases Stake in Hengrui Pharma (01276) by 1 Million Shares at HK$69.15 per Share

HENGRUI PHARMA (600276.SH): HRS-8364 Tablets Approved for Clinical Trials